Patients help highlight 'serious' side effects of drugs

   
   
  YellowCardpr
19 May 2011 14:04:00.000

PA 160/10

New research has shown that patient reporting of suspected adverse drug reactions (ADRs) is richer in detail and better at describing the impact on their daily lives than information provided by health care professionals.

The study, led by Tony Avery, Professor of Primary Care at The University of Nottingham and carried out between October 2007 and June 2010, has shown that the introduction of patient Yellow Card reporting can help to identify important side effects of medicines including serious adverse reactions and reactions that had not been previously included in pharmaceutical product literature (‘Summaries of Product Characteristics and Patient Information leaflets’).

Tony Avery, Professor of Primary Health Care in the School of Community Health Sciences at The University of Nottingham, said: “Our study has shown that patient reports of suspected adverse drug reactions add value by highlighting problems that are not commonly reported by healthcare professionals, and by providing detailed information about adverse reactions, including the impact on patients’ lives. Also, patient reports are just as likely as those from healthcare professionals to concern reactions that are considered serious.”

Click here for full story
Monitoring of suspected ADRs is vital for patient safety. The Yellow Card Scheme (YCS) run by the Medicines and Healthcare products Regulatory Agency (MHRA) is the system for reports submitted from patients and healthcare professionals on a voluntary basis.

Although the patient voice is clearly important for pharmacovigilance a survey carried out by this study found that of over 2,000 members of the public only one in 12 had heard of the Yellow Card Scheme. The surveys and a series of focus groups indentified ways in which publicity and reporting methods might be improved.

Until 2005 ADR Yellow Card reports were only accepted by the MHRA from health care professionals — after that patients were also included in the scheme. Until now there have been few studies on the views and experiences of patients on the reporting of suspected ADRs.

The study, funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme, concludes that patients could have a more significant role to play in the reporting of ADRs and more should be done to encourage them to participate in the YCS. Patient
reporters who returned questionnaires to the research team provided important insights into
patients’ experiences “Actually, no one knows better than the patient how it feels” and the YCS: “I feel it's important that medicines and their side effects are monitored.  If people who suffer the side effects report them, it's the only way the MHRA will be made aware of the problems and effects some people are experiencing from certain medications”.

Researchers from The University of Nottingham, the University of Aberdeen, Keele University, the Drug Safety Research Unit in Southampton, Liverpool John Moores University and the University of Leicester looked at the characteristics of patient reports, the types of drug and suspected ADR reported and the seriousness of reports and their contents. They sought the views and experiences of over 1,300 patient reporters and found that 93 per cent found it fairly easy or very easy to make a Yellow Card report.

Claire Anderson, Professor of Social Pharmacy, School of Pharmacy said “Raising public awareness of the scheme should be prioritised.  Our study showed that the public had often stumbled across the Yellow Card Scheme either in a pharmacy, a doctor’s surgery or via the media.”

A major report on the work is published on-line by NIHR Health Technology Assessment (www.hta.ac.uk) on Wednesday May 17, and is packed with information about the project, including a large number of illustrative quotes from patients.

MHRA’s Director of Vigilance and Risk Management of Medicines, Dr June Raine said, “Medicines have important benefits; however, they may also have side effects. We welcome the results from this important study which confirm the MHRA’s experience that patients make an important contribution to monitoring the safety of medicines through Yellow Card reporting. The findings from this study will help us continue to strengthen the role of patients as reporters to the scheme. The more reports the MHRA receives about suspected adverse drug reactions, the sooner we can relay important safety messages to the public and healthcare professionals — everyone benefits from better information”.


Members of the public wishing to know more about patient reporting to the Yellow Card Scheme, including how to make a report, can find out from the following website http://yellowcard.mhra.gov.uk/, as can healthcare professionals. Alternatively, Yellow Card report forms are available from many community pharmacies or by phoning the National Yellow Card Information Service 0808 100 3352 (10am to 2pm Monday-Friday).

On Friday June 24 2011, a conference will be held in London to further publicise the findings from the study. Further details are available from www.primm.eu.com/

For more information about the Yellow Card Scheme, or the work of Medicines and Healthcare products Regulatory Agency (MHRA) please visit www.mhra.gov.uk, telephone +44 (0)203 06 000, or email info@mhra.gsi.gov.uk

For more information about the Yellow Card Scheme, or the work of Medicines and Healthcare products Regulatory Agency (MHRA) please visit www.mhra.gov.uk, telephone +44 (0)203 06 000, or email info@mhra.gsi.gov.uk

— Ends —


Notes to editors: The National Institute for Health Research Health Technology Assessment (NIHR HTA) programme commissions research about the effectiveness, costs, and broader impact of health technologies for those who use, manage and provide care in the NHS. It is the largest NIHR programme and publishes the results of its research in the Health Technology Assessment journal, with over 550 issues published to date. The journal’s 2008 Impact Factor (6.91) ranked it in the top 10 per cent of medical and health-related journals. All issues are available for download free of charge from the website, www.hta.ac.uk

The National Institute for Health Research provides the framework through which the research staff and research infrastructure of the NHS in England is positioned, maintained and managed as a national research facility. The NIHR provides the NHS with the support and infrastructure it needs to conduct first-class research funded by the Government and its partners alongside high-quality patient care, education and training.  Its aim is to support outstanding individuals (both leaders and collaborators), working in world class facilities (both NHS and university), conducting leading edge research focused on the needs of patients. www.nihr.ac.uk


The University of Nottingham, described by The Sunday Times University Guide 2011 as ‘the embodiment of the modern international university’, has award-winning campuses in the United Kingdom, China and Malaysia. It is ranked in the UK's Top 10 and the World's Top 75 universities by the Shanghai Jiao Tong (SJTU) and the QS World University Rankings. It was named ‘Europe’s greenest university’ in the UI GreenMetric World University Ranking, a league table of the world’s most environmentally-friendly higher education institutions, which ranked Nottingham second in the world overall.

The University is committed to providing a truly international education for its 40,000 students, producing world-leading research and benefiting the communities around its campuses in the UK and Asia.

More than 90 per cent of research at The University of Nottingham is of international quality, according to the most recent Research Assessment Exercise, with almost 60 per cent of all research defined as ‘world-leading’ or ‘internationally excellent’. Research Fortnight analysis of RAE 2008 ranked the University 7th in the UK by research power. The University’s vision is to be recognised around the world for its signature contributions, especially in global food security, energy & sustainability, and health.

More news from the University at: www.nottingham.ac.uk/news

Story credits

 More information is available from Professor Tony Avery on +44 (0)115 823 0209, tony.avery@nottingham.ac.uk; or Professor Claire Anderson on 07867 505500, claire.anderson@nottingham.ac.uk
Lindsay Brooke

Lindsay Brooke - Media Relations Manager

Email: lindsay.brooke@nottingham.ac.uk Phone: +44 (0)115 951 5751 Location: University Park

Additional resources

No additional resources for this article

Related articles

Everyday medicines can destroy lives, conference warns

Published Date
Wednesday 6th July 2011

Pay for performance targets do not improve patient health

Published Date
Wednesday 26th January 2011

Antidepressants are not 'happy pills'

Published Date
Monday 25th November 2013

Nottingham Primary Care Division a UK leading centre

Published Date
Tuesday 16th June 2009

Improve management of multiple medicine use, warns report

Published Date
Friday 29th November 2013

Primary care research in Nottingham shares £30m funding boost

Published Date
Thursday 20th November 2014

'Creating a Scene'... dementia play showcases new research

Published Date
Thursday 21st July 2011

Flu, 50% of at risk patients are still not vaccinated

Published Date
Saturday 1st February 2014

One of the best researchers in general practice

Published Date
Wednesday 14th May 2008

TARDIS trial seeks new dimension in stroke treatment

Published Date
Monday 17th October 2011

Media Relations - External Relations

The University of Nottingham
C Floor, Pope Building (Room C4)
University Park
Nottingham, NG7 2RD

telephone: +44 (0) 115 951 5798
email: communications@nottingham.ac.uk